Vident Investment Advisory, LLC Ionis Pharmaceuticals Inc Transaction History

Vident Investment Advisory, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 12, 2021	SELL	$33.54 - $40.55 $187,387 - $226,552	-5,587 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$34.54 - $47.25 $192,974 - $263,985	5,587 New	5,587 $223,000
Q3 2020 Nov 12, 2020	SELL	$47.45 - $62.95 $381,165 - $505,677	-8,033 Closed	0 $0
Q2 2020 Jul 17, 2020	BUY	$46.85 - $61.05 $376,346 - $490,414	8,033 New	8,033 $474,000
Q4 2018 Feb 14, 2019	SELL	$43.37 - $59.54 $178,250 - $244,709	-4,110 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$42.88 - $53.7 $74,268 - $93,008	-1,732 Reduced 29.65%	4,110 $212,000
Q2 2018 Aug 14, 2018	BUY	$40.53 - $50.7 $2,634 - $3,295	65 Added 1.13%	5,842 $243,000
Q1 2018 May 14, 2018	BUY	$44.08 - $55.05 $5,730 - $7,156	130 Added 2.3%	5,777 $252,000
Q4 2017 Feb 15, 2018	SELL	$50.3 - $64.39 $10,110 - $12,942	-201 Reduced 3.44%	5,647 $284,000
Q3 2017 Nov 14, 2017	BUY	$45.56 - $59.57 $266,434 - $348,365	5,848	5,848 $296,000

403

136M

862K

582K

Ticker IONS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,940,992
Market Cap $5.35B
Description
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...

Get notified when there are updates to the investment portfolio of Vident Investment Advisory, LLC, based on Form 13F filings with the SEC.

Stay updated on Vident Investment Advisory, LLC with notifications on news.